YMAB - Y-mAbs Therapeutics, Inc.

QQQ $ 457.67 $ 1.46 (0.32 %)

DIA $ 403.43 $ -1.86 (-0.46 %)

SPY $ 545.17 $ -1.70 (-0.31 %)

TLT $ 100.70 $ 0.00 (0 %)

GLD $ 232.42 $ 0.81 (0.35 %)

Previous Close

$ 13.4

Open

$ 13.73

Bid

$ 13.18 x 100

Ask

$ 13.27 x 300

Day's Range

$ 13.25 - $ 13.73

52 Week Range

$ 4.69 - $ 20.90

Volume

229,279

Average Volume

Market Cap

597.24M

Beta (5Y Monthly)

$ 1.49

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	03-30-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-12-2020	12-31-2019	10-K
20	11-13-2019	09-30-2019	10-Q
21	08-14-2019	06-30-2019	10-Q
22	05-10-2019	03-31-2019	10-Q
23	03-22-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wedbush Reiterates Outperform on Y-mAbs Th...
09/10/2024 13:01:08

Wedbush analyst David Nierengarten reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and maintains $23 price ta...

Navigating 8 Analyst Ratings For Y-mAbs Th...
09/09/2024 17:00:12

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:19:00

Cantor Fitzgerald analyst Li Watsek reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight and maintains $20 price t...

Y-mAbs Therapeutics Announced New Clinical...
09/06/2024 11:32:52

Cantor Fitzgerald Initiates Coverage On Y-...
08/16/2024 11:46:02

Cantor Fitzgerald analyst Li Watsek initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight rating and ann...

Canaccord Genuity Maintains Buy on Y-mAbs ...
08/13/2024 16:26:27

Canaccord Genuity analyst Bill Maughan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $26 price target.

Assessing Y-mAbs Therapeutics: Insights Fr...
08/13/2024 14:01:03

Morgan Stanley Maintains Underweight on Y-...
08/13/2024 12:53:38

Morgan Stanley analyst Michael Ulz maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Underweight and lowers the price targe...

HC Wainwright & Co. Reiterates Buy on Y-mA...
08/13/2024 12:25:59

HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $22 price...

BMO Capital Maintains Outperform on Y-mAbs...
08/13/2024 11:36:54

BMO Capital analyst Etzer Darout maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and lowers the price target f...

Y-mAbs' Cash And Cash Equivalents Of $77.8...
08/12/2024 10:34:55

Y-mAbs' Anticipated 2024 Total Net Revenue...
08/12/2024 10:33:47

Anticipated Operating Expenses expected to remain between $115 million and $120 million;Anticipated Total Annual Cash Burn expe...

Y-mAbs Therapeutics Q2 2024 GAAP EPS $(0.2...
08/12/2024 10:31:57

why-ainos-shares-are-trading-higher-by-around-38-here-are-20-stocks-moving-premarket

Why Ainos Shares Are Trading Higher By Aro...
08/12/2024 10:04:36

Jones Trading Initiates Coverage On Y-mAbs...
07/11/2024 20:46:35

Jones Trading analyst Justin Walsh initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces P...

msc-industrial-direct-radius-recycling-and-3-stocks-to-watch-heading-into-tuesday

MSC Industrial Direct, Radius Recycling An...
07/02/2024 06:29:42

Y-mAbs Therapeutics Appoints Peter Pfreund...
07/01/2024 20:07:11

Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc.

Truist Securities Initiates Coverage On Y-...
06/28/2024 11:12:54

Truist Securities analyst Nicole Germino initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and annou...

Y-MAbs Therapeutics Says Preclinical GD2-S...
06/07/2024 11:09:22

HC Wainwright & Co. Maintains Buy on Y-mAb...
05/13/2024 17:37:53

HC Wainwright & Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price tar...